Abstract
Common fragile sites (CFSs) are regions of chromosomal break that may play a role in oncogenesis. The most frequent alteration occurs at FRA3B, within the FHIT gene, at chromosomal region 3p14. We studied a series of breast carcinomas for break of a CFS at 6q26, FRA6E, and its associated gene PARK2, using fluorescence in situ hybridization on tissue microarrays (TMA). We found break of PARK2 in 6% of cases. We studied the PARK2-encoded protein Parkin by using immunohistochemistry on the same TMA. Loss of Parkin was found in 13% of samples but was not correlated with PARK2 break. PARK2 break but not Parkin expression was correlated with prognosis. Alteration of PARK2/FRA6E may cause haplo-insufficiency of one or several telomeric potential tumor suppressor genes (TSG). The AF-6/MLLT4 gene, telomeric of PARK2, encodes the Afadin scaffold protein, which is essential for epithelial integrity. Loss of Afadin was found in 14.5% of cases, and 36% of these cases showed PARK2 break. Loss of Afadin had prognostic impact, suggesting that AF-6 may be a TSG. Loss of Afadin was correlated with loss of FHIT expression, suggesting fragility of FRA6E and FRA3B in a certain proportion of breast tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Agirre X, Roman-Gomez J, Vazquez I, Jimenez-Velasco A, Garate L, Montiel-Duarte C et al. (2005). Int J Cancer 118: 1945–1953.
Bednarek AK, Keck-Waggoner CL, Daniel RL, Laflin KJ, Bergsagel PL, Kiguchi K et al. (2001). Cancer Res 61: 8068–8073.
Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM . (2000). Cancer Res 60: 2140–2145.
Bobinnec Y, Khodjakov A, Mir LM, Rieder CL, Edde B, Bornens M . (1998a). J Cell Biol 143: 1575–1589.
Bobinnec Y, Moudjou M, Fouquet JP, Desbruyeres E, Edde B, Bornens M . (1998b). Cell Motil Cytoskeleton 39: 223–232.
Bonnet C, Boucher D, Lazereg S, Pedrotti B, Islam K, Denoulet P et al. (2001). J Biol Chem 276: 12839–12848.
Buchert M, Schneider S, Meskenaite V, Adams MT, Canaani E, Baechi T et al. (1999). J Cell Biol 144: 361–371.
Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H et al. (2003). Proc Natl Acad Sci USA 100: 5956–5961.
Charafe-Jauffret E, Ginestier C, Monville F, Fekairi S, Jacquemier J, Birnbaum D et al. (2005). Int J Oncol 27: 1307–1313.
Chin SF, Daigo Y, Huang HE, Iyer NG, Callagy G, Kranjac T et al. (2003). Mol Pathol 56: 275–279.
Delaval B, Letard S, Lelievre H, Chevrier V, Daviet L, Dubreuil P et al. (2005). Cancer Res 65: 7231–7240.
Denison SR, Callahan G, Becker NA, Phillips LA, Smith DI . (2003a). Genes Chromosomes Cancer 38: 40–52.
Denison SR, Wang F, Becker NA, Schule B, Kock N, Phillips LA et al. (2003b). Oncogene 22: 8370–8378.
Dhillon VS, Husain SA, Ray GN . (2003). Teratog Carcinog Mutagen (Suppl 1): 35–45.
Fabbri M, Iliopoulos D, Trapasso F, Aqeilan RI, Cimmino A, Zanesi N et al. (2005). Proc Natl Acad Sci USA 102: 15611–15616.
Ginestier C, Bardou VJ, Popovici C, Charafe-Jauffret E, Bertucci F, Geneix J et al. (2003). Int J Cancer 107: 854–862.
Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, Bechlian D et al. (2002). Am J Pathol 161: 1223–1233.
Guasch G, Delaval B, Arnoulet C, Xie MJ, Xerri L, Sainty D et al. (2004). Blood 103: 309–312.
Guler G, Uner A, Guler N, Han SY, Iliopoulos D, McCue P et al. (2005). Pathol Int 55: 471–478.
Hayashi Y, Raimondi SC, Look AT, Behm FG, Kitchingman GR, Pui CH et al. (1990). Blood 76: 1626–1630.
Huang TJ, Huang BJ, Liang QW, Huang CW, Fang Y . (2004). Hepatobiliary Pancreat Dis Int 3: 62–68.
Huebner K, Croce CM . (2001). Nat Rev Cancer 1: 214–221.
Huebner K, Croce CM . (2003). Br J Cancer 88: 1501–1506.
Huebner K, Druck T, Siprashvili Z, Croce CM, Kovatich A, McCue PA . (1998). Recent Results Cancer Res 154: 200–215.
Ikeda W, Nakanishi H, Miyoshi J, Mandai K, Ishizaki H, Tanaka M et al. (1999). J Cell Biol 146: 1117–1132.
Ishii H, Zanesi N, Vecchione A, Trapasso F, Yendamuri S, Sarti M et al. (2003). FASEB J 17: 1768–1770.
Johnson SA, Dubeau L, Kawalek M, Dervan A, Schonthal AH, Dang CV et al. (2003a). Mol Cell Biol 23: 3043–3051.
Johnson SA, Dubeau L, White RJ, Johnson DL . (2003b). Cell Cycle 2: 442–444.
Kerangueven F, Noguchi T, Coulier F, Allione F, Wargniez V, Simony-Lafontaine J et al. (1997). Cancer Res 57: 5469–5474.
Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S et al. (1998). Nature 392: 605–608.
Mandai K, Nakanishi H, Satoh A, Obaishi H, Wada M, Nishioka H et al. (1997). J Cell Biol 139: 517–528.
Marin I, Lucas JI, Gradilla AC, Ferrus A . (2004). Physiol Genom 17: 253–263.
Menasce LP, Orphanos V, Santibanez-Koref M, Boyle JM, Harrison CJ . (1994a). Genes Chromosomes Cancer 10: 286–288.
Menasce LP, Orphanos V, Santibanez-Koref M, Boyle JM, Harrison CJ . (1994b). Genes Chromosomes Cancer 10: 26–29.
Miki H, Okada Y, Hirokawa N . (2005). Trends Cell Biol 15: 467–476.
Millikin D, Meese E, Vogelstein B, Witkowski C, Trent J . (1991). Cancer Res 51: 5449–5453.
Negrini M, Sabbioni S, Possati L, Rattan S, Corallini A, Barbanti-Brodano G et al. (1994). Cancer Res 54: 1331–1336.
Noviello C, Courjal F, Theillet C . (1996). Clin Cancer Res 2: 1601–1606.
Orphanos V, McGown G, Hey Y, Boyle JM, Santibanez-Koref M . (1995). Br J Cancer 71: 290–293.
Paige AJ, Taylor KJ, Taylor C, Hillier SG, Farrington S, Scott D et al. (2001). Proc Natl Acad Sci USA 98: 11417–11422.
Park SW, Ludes-Meyers J, Zimonjic DB, Durkin ME, Popescu NC, Aldaz CM . (2004). Br J Cancer 91: 753–759.
Picchio MC, Martin ES, Cesari R, Calin GA, Yendamuri S, Kuroki T et al. (2004). Clin Cancer Res 10: 2720–2724.
Popescu NC . (2003). Cancer Lett 192: 1–17.
Popovici C, Zhang B, Gregoire MJ, Jonveaux P, Lafage-Pochitaloff M, Birnbaum D et al. (1999). Blood 93: 1381–1389.
Prasad R, Gu Y, Alder H, Nakamura T, Canaani O, Saito H et al. (1993). Cancer Res 53: 5624–5628.
Richards RI . (2001). Trends Genet 17: 339–345.
Rodriguez C, Causse A, Ursule E, Theillet C . (2000). Genes Chromosomes Cancer 27: 76–84.
Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G . (2002). Proc Natl Acad Sci USA 99: 3615–3620.
Saito S, Saito H, Koi S, Sagae S, Kudo R, Saito J et al. (1992). Cancer Res 52: 5815–5817.
Sato T, Fujita N, Yamada A, Ooshio T, Okamoto R, Irie K et al. (2006). J Biol Chem 281: 5288–5299.
Seki N, Kodama J, Hashimoto I, Hongo A, Yoshinouchi M, Kudo T . (2001). Int J Oncol 19: 305–310.
Smith DI, Huang H, Wang L . (1998). Int J Oncol 12: 187–196.
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al. (2003). Proc Natl Acad Sci USA 100: 8418–8423.
Sutherland GR, Baker E, Richards RI . (1998). Trends Genet 14: 501–506.
Taki T, Hayashi Y, Taniwaki M, Seto M, Ueda R, Hanada R et al. (1996). Oncogene 13: 2121–2130.
Teixeira MR, Pandis N, Heim S . (2002). Genes Chromosomes Cancer 33: 1–16.
Tibiletti MG, Bernasconi B, Furlan D, Riva C, Trubia M, Buraggi G et al. (1996). Cancer Res 56: 4493–4498.
van der Burg M, Poulsen TS, Hunger SP, Beverloo HB, Smit EM, Vang-Nielsen K et al. (2004). Leukemia 18: 895–908.
Wang F, Denison S, Lai JP, Philips LA, Montoya D, Kock N et al. (2004). Genes Chromosomes Cancer 40: 85–96.
Whitcomb BP, Mutch DG, Herzog TJ, Rader JS, Gibb RK, Goodfellow PJ . (2003). Clin Cancer Res 9: 2277–2287.
Zhadanov AB, Provance Jr DW, Speer CA, Coffin JD, Goss D, Blixt JA et al. (1999). Curr Biol 9: 880–888.
Acknowledgements
We thank F Birg and D Maraninchi for encouragements, C Chabannon for biobank sample management and JM Durey for his help with iconography. This work was supported by Institut Paoli-Calmettes, INSERM, and grants from Ligue Nationale Contre le Cancer (LNCC) (Label 2003-2006), the Association pour la Recherche contre le Cancer (ARC-3128) and Ministries of Health and Research (Cancéropôle PACA). SGU, CG and FM are supported by a fellowship from Ministry of Research and AL by a fellowship from LNCC.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Letessier, A., Garrido-Urbani, S., Ginestier, C. et al. Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. Oncogene 26, 298–307 (2007). https://doi.org/10.1038/sj.onc.1209772
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.onc.1209772
Keywords
This article is cited by
-
Selective autophagy in cancer: mechanisms, therapeutic implications, and future perspectives
Molecular Cancer (2024)
-
Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients
BMC Cancer (2019)
-
Afadin is localized at cell–cell contact sites in mesangial cells and regulates migratory polarity
Laboratory Investigation (2016)
-
Involvement of Tight Junction Plaque Proteins in Cancer
Current Pathobiology Reports (2016)
-
Loss of AF-6/afadin induces cell invasion, suppresses the formation of glandular structures and might be a predictive marker of resistance to chemotherapy in endometrial cancer
BMC Cancer (2015)
